A Study to Evaluate the Safety and Effectiveness of PCV Chemotherapy in Patients With Recurrent High-grade Glioma With IDH1/2 Mutation

Inclusion Criteria:

* A diagnosis of high-grade glioma was established by pathological method,and the recurrency of the disease is ongoing.
* The report of the pathological diagnosis contained the status of IDH gene, and showed that IDH1/2 mutation existed.
* The age of the patient is between 18 years old and 70 years old.
* The condition of the patient permits the procedure of chemotherapy using PCV schema.
* The patient is informed consent, and willing to join in this research.

Exclusion Criteria:

* The diagnosis is not recurrent high-grade glioma.
* The diagnosis of high-grade glioma was not established by pathological method.
* No molecular neuropathological report is available, or the report showed that IDH1/2 mutation did not exist.
* The age of the patient does not meet the requirement of this research.
* The condition of the patient does not permit the procedure of chemotherapy using PCV schema.
* There are other conditions that the clinicians believe that the PCV chemotherapy is not appropriate for the patient.
* The patient is not willing to join in this research.